The role of glial cells in multiple sclerosis disease progression
Authors:
Top Cited Papers
- 21 February 2022
- journal article
- review article
- Published by Springer Nature in Nature Reviews Neurology
- Vol. 18 (4) , 237-248
Abstract
Despite the development of highly effective treatments for relapsing–remitting multiple sclerosis (MS), limited progress has been made in addressing primary progressive or secondary progressive MS, both of which lead to loss of oligodendrocytes and neurons and axons, and to irreversible accumulation of disability. Neuroinflammation is central to all forms of MS. The current effective therapies for relapsing–remitting MS target the peripheral immune system; these treatments, however, have repeatedly failed in progressive MS. Greater understanding of inflammation driven by CNS-resident cells — including astrocytes and microglia — is, therefore, required to identify novel potential therapeutic opportunities. Advances in imaging, biomarker analysis and genomics suggest that microglia and astrocytes have central roles in the progressive disease process. In this Review, we provide an overview of the involvement of astrocytes and microglia at major sites of pathology in progressive MS. We discuss current and future therapeutic approaches to directly target glial cells, either to inhibit pathogenic functions or to restore homeostatic functions lost during the course of the disease. We also discuss how bidirectional communication between astrocytes and microglia needs to be considered, as therapeutic targeting of one is likely to alter the functions of the other.Keywords
This publication has 163 references indexed in Scilit:
- A TSPO ligand is protective in a mouse model of multiple sclerosisEMBO Molecular Medicine, 2013
- Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammationJournal of Neuroinflammation, 2013
- Microglial nodules in early multiple sclerosis white matter are associated with degenerating axonsActa Neuropathologica, 2013
- Differential Expression of the Glutamate Transporter GLT-1 in PancreasJournal of Histochemistry & Cytochemistry, 2011
- Pathogenic implications of iron accumulation in multiple sclerosisJournal of Neurochemistry, 2011
- FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P 1 ) modulationProceedings of the National Academy of Sciences, 2010
- Allosteric inhibition of macrophage migration inhibitory factor revealed by ibudilastProceedings of the National Academy of Sciences, 2010
- Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for molecules associated with metabolism, signaling and regulation in central nervous system mixed glial cell culturesJournal of Neuroinflammation, 2009
- Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammationBrain, 2008
- Differential changes in junctional complex proteins suggest the ependymal lining as the main source of leukocyte infiltration into ventricles in murine neurocysticercosisJournal of Neuroimmunology, 2007